Table 1 Patient characteristics
Variables | n = 60 | |
|---|---|---|
Age, y, median (IQR) | 72.0 (56–93) | |
ECOG-PS, No. (%) | 0 | 55 (91.7) |
1 | 5 (8.3) | |
Baseline PSA level, ng/ml, median (IQR) | 195.0 (53.0–610.9) | |
Baseline Hb level, g/dl, median (IQR) | 13.2 (12.0–14.5) | |
Baseline ALP level, IU, median (IQR) | 320.0 (232.0–620.5) | |
Baseline LDH level, IU, median (IQR) | 203.0 (174.0–251.0) | |
Biopsy Gleason Score, No. (%) | ≤8 | 18 (30.0) |
≥9 | 42 (70.0) | |
Site of metstasis, No. (%) | Bone | 100 (100) |
Lymphnode | 26 (43.3) | |
Visceral | 2 (3.3) | |
Presence of bone pain, No. (%) | 25 (41.7) | |
EOD score, No. (%) | 1 | 28 (46.7) |
2 | 7 (11.7) | |
3 | 11 (18.3) | |
4 | 9 (15.0) | |
CHAARTED criteria, No. (%) | unknown | 5 (8.3) |
low | 25 (41.7) | |
high | 30 (50.0) | |
unknown | 5 (8.3) | |
PSA level at 12 weeks, ng/ml, median (IQR) | 2.6 (0.5–9.3) | |
Hb level at 12 weeks, g/dl, median (IQR) | 12.5 (11.3–13.3) | |
ALP level at 12 weeks, IU, median (IQR) | 284.0 (233.5–536.0) | |
LDH levelat 12 weeks, IU, median (IQR) | 198.0 (177.0–247.5) | |
PSA change (baseline-12wks), ng/ml, median (IQR) | 159.5 (34.4–546.9) | |
PSA change at 12 weeks,%, median (IQR) | 98.5 (94.4–99.6) |